EpiCept Corp.
Symbol:
EPCT
Exchange:
Nasdaq
Industry:
Health Care
Products:
Drugs
Company Website: Click Here
Company Info: Click Here
Quote and News: Click Here
Profiled Price:
$0.75
(August 28)
Company Snapshot:
EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company’s lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company’s pain portfolio includes EpiCeptTM NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.
|
